A phase i study of chemically synthesized verotoxin (shiga-like toxin) pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome

Glen D. Armstrong, Peter C. Rowe, Paul Goodyer, Elaine Orrbine, Terry P. Klassen, George Wells, Andrew Mac Kenzie, Hermy Lior, Colline Blanchard, Francois Auclair, Brad Thompson, David J. Rafter, Peter N. Mc Laine

Research output: Contribution to journalArticlepeer-review

Abstract

A double-blind, placebo-eontrolled study was conducted to document possible side effects associated with oral consumption of synthetic verotoxin (VT, shiga-like toxin) Pk-trisaccharide receptor sequences attached to Chromosorb (Synsorb-Pk) by healthy adult volunteers. Synsorb-Pk reclaimed from volunteer stool samples was also analyzed to determine if its VT-binding activity was affected by exposure to the pH extremes and digestive processes of the human gastrointestinal tract. No participant reported any Synsorb-Pk-related adverse reactions, and no clinically important trends in laboratory data were evident. Synsorb-Pk recovered from stools retained its ability to absorb VT in polymyxin extracts of VT-producing Escherichia coli and also neutralized VT when mixed in vitro with VT-positive stools from children with hemorrhagic colitis or hemolytic-uremic syndrome (HUS). These results suggest a potential use for Synsorb-Pk in preventing HUS in patients infected with VT-producing E. coli.

Original languageEnglish (US)
Pages (from-to)1042-1045
Number of pages4
JournalJournal of Infectious Diseases
Volume171
Issue number4
DOIs
StatePublished - Apr 1995
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A phase i study of chemically synthesized verotoxin (shiga-like toxin) pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome'. Together they form a unique fingerprint.

Cite this